New BARDA award: AstraZeneca USA Product Name: A
Post# of 36536
(Total Views: 388)
Posted On: 06/09/2020 10:20:47 AM
New BARDA award: AstraZeneca USA
Product Name: AstraZeneca SARS-CoV-2 monoclonal antibody combination
View Announcement
Description:
Support development of a monoclonal antibody combination against SARS-CoV-2
Unique Impact:
A novel monoclonal antibody combination that recognizes and neutralizes SARS-CoV-2 is being developed by AstraZeneca with DARPA and BARDA as a potential preventative and post-exposure treatment to combat COVID-19.
Award Amount: $23,650,000.00
Cost Share: Yes
Product Name: AstraZeneca SARS-CoV-2 monoclonal antibody combination
View Announcement
Description:
Support development of a monoclonal antibody combination against SARS-CoV-2
Unique Impact:
A novel monoclonal antibody combination that recognizes and neutralizes SARS-CoV-2 is being developed by AstraZeneca with DARPA and BARDA as a potential preventative and post-exposure treatment to combat COVID-19.
Award Amount: $23,650,000.00
Cost Share: Yes
(0)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼